Stock Ratings / Health Care / RLMD / earnings

SPRY (27) EBS (53) CYPH (40) GALT (42) ⌘ Pro Terminal →

Relmada Therapeutics Inc. (RLMD) Next Earnings Date & Expected ±12.5% Move

$3.44 +2.69% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Relmada Therapeutics Inc. (RLMD) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $366.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-6.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RLMD)Realized 20D OHLCV Swing Band: ±12.5%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.43 Expected Swing

MODEL EARNINGS SETUP GAUGE

RLMD Quantitative Pre-Earnings Setup: 44/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (44/100)Model Risk Weight (56/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$0	$0	-$45.8M	52%
FY 2024	2024-12-31	$0	$0	-$51.8M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RLMD)

✓Walkthrough of RLMD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

RLMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -54.26%▲ RESISTANCE BREAKOUT

2026-10-30O $3.42H $3.65L $3.30C $3.44VOL 1.41M

RES: $3.36SUP: $2.64SMA50: $3.84SMA200: $5.36

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RLMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RLMD Butterfly Map → + Track RLMD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RLMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RLMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for RLMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RLMD)

Health Care Rank #510 of 1016 ⚔️ SPRY vs RLMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RLMD vs. SPRY, EBS, CYPH, GALT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Relmada Therapeutics Inc. (RLMD) ranks #510 by composite RQD confidence (44/100, grade D) and #494 by equity capitalization ($366.9M). Within this direct 5-issuer industry benchmark cohort, EBS leads on earnings valuation at 7.0x trailing P/E, while EBS leads on capital efficiency and profitability with 8.9% ROIC and 56.1% gross margin. EBS currently holds the highest overall quantitative score in the immediate peer group at 53/100 (D+) compared with RLMD at 44/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
RLMD ACTIVE Relmada Therapeutics Inc.	D	44/100	—	—	-35.0%	+2.69%	$366.9M	Benchmark Subject
SPRY ARS Pharmaceuticals Inc.	E	27/100	—	—	-35.0%	+0.27%	$364.0M	/spry-vs-rlmd →
EBS Emergent BioSolutions Inc.	D+	53/100	7.0x	56.1%	8.9%	+1.83%	$370.2M	/ebs-vs-rlmd →
CYPH Cypherpunk Technologies Inc.	D-	40/100	71.3x	—	-23.3%	+2.16%	$356.7M	/cyph-vs-rlmd →
GALT Galectin Therapeutics Inc.	D-	42/100	—	—	-35.0%	-0.56%	$355.8M	/galt-vs-rlmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001553643

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Relmada Therapeutics Inc. (RLMD) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $0, operating cash flow of -$45.8M, and free cash flow of -$45.8M (+11.5% YoY). On the balance sheet, RLMD closed FY2025 with $94.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	-$45.8M	-$45.8M	$94.0M	—
FY2024 (FY)	2024-12-31	$0	$0	-$51.8M	-$51.8M	$45.8M	—

3. RLMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RLMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Relmada Therapeutics Inc. (NASDAQ: RLMD) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $3.44 (+2.69% 1D, market cap $366.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, RLMD ranks #510 in composite RQD confidence.

How does RLMD compare to SPRY and EBS in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RLMD carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SPRY (ARS Pharmaceuticals Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $364.0M) and EBS (Emergent BioSolutions Inc.) posts a D+ grade (53/100 RQD, P/E 7.0x, ROIC 8.9%, cap $370.2M). Among the 5-stock peer group, EBS leads on earnings multiple (7.0x) while EBS leads on capital efficiency (8.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RLMD?

Per RLMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001553643), Relmada Therapeutics Inc. generated $0 in revenue, $0 in net income, and -$45.8M in free cash flow against $94.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RLMD trading relative to its 50-day, 200-day, and 52-week technical levels?

RLMD last traded at $3.44 (+2.69% on volume of 1,610,452 shares), positioning the stock -10.42% below its 50-day simple moving average ($3.84) and -35.82% below its 200-day simple moving average ($5.36). Across its 52-week range of $2.15 to $8.00, RLMD sits at the 22.1% percentile with a 14-day RSI of 52.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.01 to $3.87).